Navigation Links
Stage at Breast Cancer Diagnosis Will Shift Dramatically Over the Next 20 Years in Key Latin American Markets
Date:11/5/2013

BURLINGTON, Mass., Nov. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that with increased awareness and investment in national breast cancer screening programs, the stage at diagnosis of breast cancer in the key Latin American markets is set to shift dramatically over the next 20 years. According to findings from the Strategic Insights report The Impact of Economic Growth on Patient Populations: Breast Cancer Populations in Latin America, the drug-treatable breast cancer patient population will also increase, driven by a rapidly expanding and aging population and earlier stages at diagnosis. Specifically, the adjuvant and neoadjuvant drug-treatable population will increase by 51 percent and the first-line drug-treatable population will increase by 21 percent over the next 10 years.

The findings also reveal that in the adjuvant and neoadjuvant setting in Brazil and Mexico, with HR+ and HER2-overexpressing tumors present in 70 percent and 22 percent of Latin American breast cancer cases, respectively, the growth in hormone therapy and HER2-targeted agents is expected to increase by 51 percent over the next 10 years.

"The risk of breast cancer will increase in Brazil and Mexico as they become more affluent and adopt more-Westernized lifestyles—a key indicator of breast cancer risk," said Decision Resources Senior Epidemiologist Alison Isherwood, Ph.D. "The increasing population, increasing risk of breast cancer and shifting to earlier stages at diagnosis are all driving the increase in the drug-treatable breast cancer populations, so marketers of breast cancer drugs will find significant opportunity in this region."

Countries included in the analysis are Argentina, Brazil, Chile, Colombia, Mexico and Venezuela.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
4. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
5. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
6. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
7. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
8. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
9. Telescope Implant for End Stage Macular Degeneration Now Available Across the Nation
10. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
11. Pharmaceutical Packaging is at the Centre Stage of Pharma Manufacturing!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):